Grundlæggende statistik
| CIK | 887497 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Hi-Tech Pharmacal Co.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| April 28, 2014 |
- HI-TECH PHARMACAL CO., INC. FORM 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 000-20424 Hi-Tech Pharmacal Co., Inc. (Exact name of registrant as specifie |
|
| April 21, 2014 |
HITK / Hi-Tech Pharmacal Co. / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Hi-Tech Pharmacal Co., Inc. (Name of Issuer) Common Stock, $.01 Par Value (Title of Class of Securities) 42840B101 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Per |
|
| April 17, 2014 |
As filed with the Securities and Exchange Commission on April 17, 2014 Registration Nos. |
|
| April 17, 2014 |
As filed with the Securities and Exchange Commission on April 17, 2014 Registration Nos. |
|
| April 17, 2014 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION HI-TECH PHARMACAL CO., INC. ARTICLE ONE Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF HI-TECH PHARMACAL CO., INC. ARTICLE ONE The name of the corporation is Hi-Tech Pharmacal Co., Inc. (hereinafter called the “Corporation”). ARTICLE TWO The address of the Corporation’s registered office in the state of Delaware is Corporation Service Company, 2711 Centerville Road, Suite 400, in the City of Wilmington, in the County o |
|
| April 17, 2014 |
As filed with the Securities and Exchange Commission on April 17, 2014 Registration Nos. |
|
| April 17, 2014 |
As filed with the Securities and Exchange Commission on April 17, 2014 Registration Nos. |
|
| April 17, 2014 |
Akorn Completes Acquisition of Hi-Tech Pharmacal EX-99.1 4 v375079ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Akorn Completes Acquisition of Hi-Tech Pharmacal LAKE FOREST, IL— April 17, 2014 – Akorn, Inc. (NASDAQ: AKRX), a niche pharmaceutical company, announced today that it has completed its previously announced acquisition of Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) for $640 million in cash. The combination of Akorn and Hi-Te |
|
| April 17, 2014 |
As filed with the Securities and Exchange Commission on April 17, 2014 Registration Nos. |
|
| April 17, 2014 |
As filed with the Securities and Exchange Commission on April 17, 2014 Registration Nos. |
|
| April 17, 2014 |
S-8 POS 1 v375102s8pos.htm FORM 333-139796 As filed with the Securities and Exchange Commission on April 17, 2014 Registration Nos. 333-35425, 333-108473, 333-126872, 333-139796, 333-155407, 333-168458, 333-171395, 333-181580, 333-188150, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 (No. 333-35425) POST-EFFECTIVE AMENDMENT NO. 1 |
|
| April 17, 2014 |
As filed with the Securities and Exchange Commission on April 17, 2014 Registration Nos. |
|
| April 17, 2014 |
EX-3.2 3 v375079ex3-2.htm EXHIBIT 3.2 Exhibit 3.2 SECOND AMENDED AND RESTATED BY-LAWS OF HI-TECH PHARMACAL CO., INC., A Delaware corporation (Adopted as of April 17, 2014) Article I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be located at 2711 Centerville Road, Suite 400, in the City of Wilmington, in the County of New Castle, Dela |
|
| April 17, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 17, 2014 Hi-Tech Pharmacal Co., Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-20424 (Commission File Nu |
|
| April 17, 2014 |
As filed with the Securities and Exchange Commission on April 17, 2014 Registration Nos. |
|
| March 21, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) March 18, 2014 HI-TECH PHARMACAL CO. |
|
| March 21, 2014 |
SEPARATION AGREEMENT AND GENERAL RELEASE SEPARATION AGREEMENT AND GENERAL RELEASE This SEPARATION AGREEMENT AND GENERAL RELEASE (“Agreement”) is made as of this 25th day of February, 2014 by and between Hi-Tech Pharmacal Co. |
|
| March 20, 2014 |
HITK / Hi-Tech Pharmacal Co. / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Hi-Tech Pharmacal Co., Inc. (Name of Issuer) Common Stock, $.01 Par Value (Title of Class of Securities) 42840B101 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Per |
|
| March 13, 2014 |
HITK / Hi-Tech Pharmacal Co. / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Hi-Tech Pharmacal Co., Inc. (Name of Issuer) Common Stock, $.01 Par Value (Title of Class of Securities) 42840B101 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorized to |
|
| March 12, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) March 11, 2014 HI-TECH PHARMACAL CO. |
|
| March 12, 2014 |
Hi-Tech Pharmacal Reports Sales of $59.9 million for the Third Quarter Ended January 31, 2014 EXHIBIT 99.1 Hi-Tech Pharmacal Reports Sales of $59.9 million for the Third Quarter Ended January 31, 2014 AMITYVILLE, N.Y – March 11, 2014 – Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the third fiscal quarter ended January 31, 2014. · Net sales of $59.9 million for the third quarter compared to $64.3 million for the same prior year period · GAAP income of $8.4 million o |
|
| March 11, 2014 |
Form 10-Q Table of Contents United States Securities and Exchange Commission Washington, D. |
|
| February 12, 2014 |
HITK / Hi-Tech Pharmacal Co. / AQR CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Hi-Tech Pharmacal Co., Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 42840B101 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 11, 2014 |
HITK / Hi-Tech Pharmacal Co. / AQR DELTA Master Acccount, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hi-Tech Pharmacal Co., Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 42840BB101 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| December 26, 2013 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 26, 2013 HI-TECH PHARMACAL CO. |
|
| December 26, 2013 |
Hi-Tech Pharmacal Announces Settlement Regarding Texas Pricing Investigation Exhibit 99.1 Hi-Tech Pharmacal Announces Settlement Regarding Texas Pricing Investigation AMITYVILLE, N.Y – December 26, 2013 – Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that the Texas Attorney General has agreed to close its investigation of Hi-Tech’s pricing of products that were purchased with Texas Medicaid dollars. In settlement, Hi-Tech agreed to pay $25,000,000 to the State |
|
| December 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 19, 2013 HI-TECH PHARMACAL CO. |
|
| December 10, 2013 |
Form 10-Q Table of Contents United States Securities and Exchange Commission Washington, D. |
|
| December 10, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 v3626748-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 10, 2013 HI-TECH PHARMACAL CO., INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) |
|
| December 10, 2013 |
AMENDED AND RESTATED HI-TECH PHARMACAL CO., INC. ARTICLE I Stockholders’ Meetings EX-3.3 Exhibit 3.3 AMENDED AND RESTATED BY-LAWS OF HI-TECH PHARMACAL CO., INC. ARTICLE I Stockholders’ Meetings 1. Places of meetings. All meetings of stockholders shall be held at such place or places in or outside of the State of Delaware as the board of directors may from time to time determine or as may be designated in the notice of meeting or waiver of notice thereof, subject to any provisio |
|
| December 10, 2013 |
Table I Hi-Tech Pharmacal Co., Inc. Reconciliation of Non-GAAP Measures EXHIBIT 99.1 Hi-Tech Pharmacal Reports Sales of $58.6 million for the Second Quarter Ended October 31, 2013 AMITYVILLE, N.Y – December 10, 2013 – Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the second fiscal quarter ended October 31, 2013. • Net sales of $58.6 million for the second quarter compared to $57.5 million for the same prior year period • GAAP income of $1.2 mil |
|
| November 27, 2013 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Pro |
|
| November 7, 2013 |
Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to Section 240. |
|
| October 11, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 11, 2013 Hi-Tech Pharmacal Co., Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-20424 11-2638720 (State or Other Jurisdiction (Commission File Number) (IR |
|
| October 8, 2013 |
HITK / Hi-Tech Pharmacal Co. / AQR DELTA Master Acccount, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Hi-Tech Pharmacal Co., Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 42840BB101 (CUSIP Number) September 24, 2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| September 24, 2013 |
Preliminary Proxy Statement Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to Section 240. |
|
| September 16, 2013 |
HI-TECH PHARMACAL CO., INC. 369 BAYVIEW AVENUE AMITYVILLE, NY 11701 Exhibit 10.7 HI-TECH PHARMACAL CO., INC. 369 BAYVIEW AVENUE AMITYVILLE, NY 11701 September 12, 2013 Mr. Gary M. April 17 Alley Pond Court Dix Hills, NY 11746 Dear Mr. April: Reference is made to that certain letter agreement, dated October 18, 2011, by and between Hi-Tech Pharmacal Co., Inc. (the “Company”) and you in connection with your employment (the “Letter Agreement”). All terms not defined |
|
| September 16, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) September 12, 2013 HI-TECH PHARMACAL CO. |
|
| September 10, 2013 |
Table I Hi-Tech Pharmacal Co., Inc. Reconciliation of Non-GAAP Measures EX-99.1 2 v354664ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 Hi-Tech Pharmacal Reports Sales of $50.5 million for the First Quarter Ended July 31, 2013 AMITYVILLE, N.Y – September 9, 2013 – Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the Company’s fiscal first quarter ended July 31, 2013. • Net sales of $50.5 million for the first quarter compared to $52.0 million for the same p |
|
| September 10, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) September 9, 2013 HI-TECH PHARMACAL CO. |
|
| September 9, 2013 |
Hi-Tech Pharmacal FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents United States Securities and Exchange Commission Washington, D. |
|
| September 5, 2013 |
HITK / Hi-Tech Pharmacal Co. / AKORN INC - AKORN, INC. SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Hi-Tech Pharmacal Co., Inc. (Name of Issuer) Common stock, par value $0.01 per share (Title of Class of Securities) 42840B101 (CUSIP Number) Joseph Bonaccorsi Senior Vice President, General Counsel and Secretary Akorn, Inc. 1925 W. Field Court, Suite 300 Lake Forest, Illin |
|
| September 5, 2013 |
FORM OF JOINDER TO VOTING AGREEMENT EX-3 2 a50703425ex3.htm EXHIBIT 3 EXHIBIT 3 FORM OF JOINDER TO VOTING AGREEMENT THIS JOINDER to the Voting Agreement, dated as of August 26, 2013, by and among Akorn, Inc., a Delaware corporation (“Parent”) and the stockholders of Hi-Tech Pharmacal Co., Inc., a Delaware corporation (the “Company”), listed on the signature pages hereto (each a “Stockholder” and collectively, the “Stockholders”), as |
|
| September 5, 2013 |
EX-4 3 a50703425ex4.htm EXHIBIT 4 EXHIBIT 4 August 26, 2013 Akorn, Inc. 1925 W. Field Court, Suite 300 Lake Forest, Illinois 60045 Attention: Timothy Dick, Chief Financial Officer Project Ice Commitment Letter Ladies and Gentlemen: You have advised JPMorgan Chase Bank, N.A. (“JPMCB”) and J.P. Morgan Securities LLC (“JPMorgan”; and together with JPMCB, the “Commitment Parties,” “us” or “we”), that |
|
| August 27, 2013 |
Exhibit 99.2 FOR IMMEDIATE RELEASE Akorn to Acquire Hi-Tech Pharmacal for $640 Million - Over $500 million in combined revenues – - Immediately accretive to non-GAAP earnings, before synergies – - $15-20 million in annual run-rate synergies expected within 12 months post-close – - Strong combined cash flow allows for rapid pay-down of debt - LAKE FOREST, IL— August 27, 2013 - Akorn, Inc. (NASDAQ: |
|
| August 27, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 27, 2013 (August 26, 2013) Hi-Tech Pharmacal Co., Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-20424 11-2638720 (State or Other Jurisdiction (Commission |
|
| August 27, 2013 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER between AKORN, INC., AKORN ENTERPRISES, INC. and HI-TECH PHARMACAL CO., INC. dated as of August 26, 2013 TABLE OF CONTENTS Page ARTICLE I THE MERGER 1 Section 1.1 The Merger 1 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Section 1.4 Effects of the Merger 2 Section 1.5 Certificate of Incorporation; Bylaws 2 Section 1.6 Directors; Officers 2 ARTICLE II |
|
| August 27, 2013 |
Exhibit 99.1 EXECUTION VERSION VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”), dated as of August 26, 2013, by and among Akorn, Inc., a Louisiana corporation (“Parent”), and the stockholders of Hi-Tech Pharmacal Co., Inc., a Delaware corporation (the “Company”), listed on the signature pages hereto (each a “Stockholder” and collectively, the “Stockholders”). W I T N E S S E T H: WHEREAS |
|
| August 27, 2013 |
Exhibit 99.1 EXECUTION VERSION VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”), dated as of August 26, 2013, by and among Akorn, Inc., a Louisiana corporation (“Parent”), and the stockholders of Hi-Tech Pharmacal Co., Inc., a Delaware corporation (the “Company”), listed on the signature pages hereto (each a “Stockholder” and collectively, the “Stockholders”). W I T N E S S E T H: WHEREAS |
|
| August 27, 2013 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER between AKORN, INC., AKORN ENTERPRISES, INC. and HI-TECH PHARMACAL CO., INC. dated as of August 26, 2013 TABLE OF CONTENTS Page ARTICLE I THE MERGER 1 Section 1.1 The Merger 1 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Section 1.4 Effects of the Merger 2 Section 1.5 Certificate of Incorporation; Bylaws 2 Section 1.6 Directors; Officers 2 ARTICLE II |
|
| August 27, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 27, 2013 (August 26, 2013) Hi-Tech Pharmacal Co., Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-20424 11-2638720 (State or Other Jurisdiction (Commission |
|
| August 27, 2013 |
Exhibit 99.2 FOR IMMEDIATE RELEASE Akorn to Acquire Hi-Tech Pharmacal for $640 Million - Over $500 million in combined revenues – - Immediately accretive to non-GAAP earnings, before synergies – - $15-20 million in annual run-rate synergies expected within 12 months post-close – - Strong combined cash flow allows for rapid pay-down of debt - LAKE FOREST, IL— August 27, 2013 - Akorn, Inc. (NASDAQ: |
|
| August 13, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) August 8, 2013 HI-TECH PHARMACAL CO. |
|
| August 13, 2013 |
AMENDMENT NO. 4 TO EMPLOYMENT AGREEMENT Exhibit 10.5 AMENDMENT NO. 4 TO EMPLOYMENT AGREEMENT AMENDMENT NO. 4, dated August 8, 2013, to that certain Employment Agreement, dated as of August 1, 2005, as amended by Amendment No.1, Amendment No. 2 and Amendment No. 3 dated October 30, 2007, June 30, 2009 and September 2, 2011, respectively (the employment agreement, as amended hereinafter referred to as the “Employment Agreement”), by and b |
|
| August 13, 2013 |
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT Exhibit 10.6 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT AMENDMENT NO. 1, dated August 9, 2013, to that certain Employment Agreement, dated as of November 10, 2010 (the employment agreement as amended hereinafter referred to as the “Employment Agreement”), by and between Hi-Tech Pharmacal Co., Inc. (the “Corporation”) and Reuben Seltzer (the “Executive”). WHEREAS, for good and valuable consideration, |
|
| July 24, 2013 |
Health Care Products Division of Hi-Tech Pharmacal Receives FDA Warning Letter Exhibit 99.1 Health Care Products Division of Hi-Tech Pharmacal Receives FDA Warning Letter Related to Labeling Statements on Certain OTC Products Amityville, NY - July 24, 2013 - Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that its Health Care Products Over The Counter (OTC) division received a Warning Letter from Food and Drug Administration (FDA) dated July 15, 2013. The Warning |
|
| July 24, 2013 |
8-K 1 v3507678k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) July 24, 2013 HI-TECH PHARMACAL CO., INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) No. |
|
| July 11, 2013 |
Hi-Tech Pharmacal FORM 10-K (Annual Report) 10-K 1 d521739d10k.htm FORM 10-K Table of Contents U.S. Securities and Exchange Commission Washington, D.C. 20549 Form 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended April 30, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-20424 Hi |
|
| July 9, 2013 |
Table I Hi-Tech Pharmacal Co., Inc. Reconciliation of Non-GAAP Measures Exhibit 99.1 Hi-Tech Pharmacal Reports Sales of $58.5 million for the Fourth Quarter Ended April 30, 2013 AMITYVILLE, N.Y – July 9, 2013 – Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the fourth quarter and year ended April 30, 2013. • Net sales of $58.5 million for the fourth quarter compared to $61.3 million for the same prior year period • GAAP loss of $4.6 million or $ |
|
| July 9, 2013 |
Results of Operations and Financial Condition - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) July 9, 2013 HI-TECH PHARMACAL CO. |
|
| May 31, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 31, 2013 HI-TECH PHARMACAL CO. |
|
| May 31, 2013 |
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), dated as of May 1, 2013, by and between HI-TECH PHARMACAL CO. |
|
| May 28, 2013 |
Exhibit 99.1 Amended and Restated Employment Agreement of Kamel Egbaria AMENDED and RESTATED EMPLOYMENT AGREEMENT, as of May 22, 2013, by and between HI-TECH PHARMACAL CO., INC., a Delaware corporation with offices at 369 Bayview Avenue, Amityville, New York 11701 (the “Corporation”), and KAMEL EGBARIA, an individual residing at 57 Foxwood Drive, Jericho, New York 11753 (“Executive”). WITNESSETH W |
|
| May 28, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 22, 2013 HI-TECH PHARMACAL CO. |
|
| April 26, 2013 |
As filed with the Securities and Exchange Commission on April 26, 2013 Registration No. |
|
| March 13, 2013 |
EMPLOYMENT AGREEMENT, as of January 1, 2013, by and between ECR PHARMACEUTICALS CO. |
|
| March 13, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) March 11, 2013 HI-TECH PHARMACAL CO. |
|
| March 8, 2013 |
Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) March 7, 2013 HI-TECH PHARMACAL CO. |
|
| March 8, 2013 |
Exhibit 99.1 Hi-Tech Pharmacal Reports Sales of $64.3 Million and EPS of $0.43 for the Third Quarter Ended January 31, 2013 AMITYVILLE, N.Y. – March 7, 2013 - Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the Company’s fiscal third quarter ended January 31, 2013. Quarterly Results Net sales for the three months ended January 31, 2013 were $64,331,000, an increase of $8,706, |
|
| February 14, 2013 |
HITK / Hi-Tech Pharmacal Co. / SELTZER DAVID S - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 15)* HI-TECH PHARMACAL CO., INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 42840B101 (CUSIP Number) December 31, 2012 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2013 |
HITK / Hi-Tech Pharmacal Co. / SELTZER REUBEN - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11)* HI-TECH PHARMACAL CO., INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 42840B101 (CUSIP Number) December 31, 2012 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| December 6, 2012 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 6, 2012 HI-TECH PHARMACAL CO. |
|
| December 6, 2012 |
Exhibit 99.1 Hi-Tech Pharmacal Reports Sales of $57.5 Million and EPS of $0.66 for the Second Quarter Ended October 31, 2012 AMITYVILLE, N.Y. - December 6, 2012 - Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the Company’s fiscal second quarter ended October 31, 2012. Quarterly Results Net sales for the three months ended October 31, 2012 were $57,537,000, an increase of $6 |
|
| November 30, 2012 |
Hi-Tech Pharmacal Announces Special Dividend of $1.50 per Share EXHIBIT 99.1 Hi-Tech Pharmacal Announces Special Dividend of $1.50 per Share AMITYVILLE, N.Y. - November 30, 2012- Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) announced that it will pay a special one-time dividend of $1.50 per share. The dividend will be payable on December 28, 2012 to shareholders of record on December 13, 2012. David Seltzer, President and CEO commented on the dividend: “This spec |
|
| November 30, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) November 30, 2012 HI-TECH PHARMACAL CO. |
|
| November 8, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) November 7, 2012 HI-TECH PHARMACAL CO. |
|
| September 28, 2012 |
Definitive Proxy Statement SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to Section 240. |
|
| September 5, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) September 5, 2012 HI-TECH PHARMACAL CO. |
|
| September 5, 2012 |
EXHIBIT 99.1 Hi-Tech Pharmacal Reports Sales of $52.0 Million and EPS of $0.44 for the First Quarter Ended July 31, 2012 AMITYVILLE, N.Y. - September 5, 2012 - Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the Company’s fiscal first quarter ended July 31, 2012. Quarterly Results Net sales for the three months ended July 31, 2012 were $52,043,000, a decrease of $4,168,000 or |
|
| July 11, 2012 |
EXHIBIT 99.1 Hi-Tech Pharmacal Reports Sales of $61.3 million and Diluted EPS of $0.73 for the Fourth Quarter 2012 Ended April 30, 2012 AMITYVILLE, N.Y – July 10, 2012 – Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the fourth quarter and year ended April 30, 2012. Fourth Quarter Results For the three months ended April 30, 2012, the Company reported net sales of $61.3 mill |
|
| July 11, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, 8-K - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) July 10, 2012 HI-TECH PHARMACAL CO. |
|
| May 22, 2012 |
Form S-8 As filed with the Securities and Exchange Commission on May 22, 2012 Registration No. |
|
| March 8, 2012 |
Exhibit 99.1 Hi-Tech Pharmacal Reports Sales of $55.6 Million and EPS of $0.79 for the Third Quarter Ended January 31, 2012 AMITYVILLE, N.Y. – March 8, 2012 - Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the Company’s fiscal third quarter ended January 31, 2012. Quarterly Results Net sales for the three months ended January 31, 2012 were $55,625,000, an increase of $5,925, |
|
| March 8, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, 8-K - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) March 8, 2012 HI-TECH PHARMACAL CO. |
|
| February 10, 2012 |
HITK / Hi-Tech Pharmacal Co. / Visium Asset Management, LP - AMENDMENT NO. 3 Passive Investment Amendment No. 3 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Hi-Tech Pharmacal Co., Inc. (Name of Issuer) COMMON STOCK, $.001 PER SHARE (Title of Class of Securities) 42840B101 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 10, 2012 |
HITK / Hi-Tech Pharmacal Co. / SELTZER DAVID S - AMENDMENT TO FORM SC13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 14)* HI-TECH PHARMACAL CO., INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 42840B101 (CUSIP Number) December 31, 2011 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 10, 2012 |
HITK / Hi-Tech Pharmacal Co. / SELTZER REUBEN - AMENDMENT TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* HI-TECH PHARMACAL CO., INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 42840B101 (CUSIP Number) December 31, 2011 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
